NCT01801137View on ClinicalTrials.gov

The Efficacy of RAD 001 as Second Line Therapy in Patients With Transitional Cell Carcinoma TCC of the Urothelium

PHASE2CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
Urothelial Cancer
Interventions
DRUG

Everolimus (Afinitor®)

Trial Locations (1)

92150

Hôpital FOCH, Suresnes

All Listed Sponsors
lead

Hopital Foch

OTHER

NCT01801137 - The Efficacy of RAD 001 as Second Line Therapy in Patients With Transitional Cell Carcinoma TCC of the Urothelium | Biotech Hunter | Biotech Hunter